ALNYLAM AWARDED $23 MILLION U.S. GOVERNMENT CONTRACT TO DEVELOP RNAI THERAPEUTICS FOR BIOLOGICAL THREATS

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced that the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), has awarded the company a contract to advance the development of a broad spectrum RNAi anti-viral therapeutic against hemorrhagic fever virus, including the Ebola virus.

BioSpace (http://www.biospace.com/news_story.aspx?StoryID=31520&full=1)